Market Insider

Early movers: NKE, MU, CELG, RIO, DIS, SNY, AMZN, TMUS & more

Traders work on the floor of the New York Stock Exchange.
Getty Images

Check out which companies are making headlines before the bell:

Nike — The athletic footwear and apparel maker's quarterly profit came in 4 cents above estimates at 90 cents per share, although revenue was slightly below forecasts. The stock is getting a particular boost from a 20 percent increase in future orders, a number which excludes the impact of currency fluctuations.

Micron Technology — Micron earned an adjusted 24 cents per share for its latest quarter, 1 cent above estimates, while the chipmaker's revenue was below forecasts. Additionally, Micron issued current quarter guidance that falls below analysts' forecasts, as demand for personal computers weakens and prices drop.

Celgene — Celgene settled a long-running patent dispute involving its blood cancer drug Revlimid. The settlement allows India-based drugmaker Natco and a subsidiary of Allergan to sell a generic version of the drug in the US beginning in March 2022.

Rio Tinto, BHP Billiton, ArcelorMittal — These and other mining and resources companies are trading higher, following a published report in China saying steelmakers and other commodity producers are likely to slash production in 2016.

Church & Dwight — Church & Dwight will replace chipmaker Altera in the on Monday afternoon, following the close of Intel's purchase of Altera. Church & Dwight, a maker of household products such as Arm & Hammer baking soda, will be replaced in the S&P MidCap 400 by business services provider SYNNEX Corp.

Walt Disney — Disney is reportedly in talks to exit its stake in cable and digital news network Fusion, which it jointly owns with Univision. The Wall Street Journal said the two sides are seeking to finalize the deal before year's end.

Sanofi — Sanofi has submitted its new once-a-day insulin injection treatment for U.S. Food and Drug Administration (FDA) approval, with the French drugmaker asking the agency for an expedited six-month review. FDA reviews normally take 10 months.

Alphabet — Alphabet's Google unit is building a new mobile-messaging app using artificial intelligence technology, according to The Wall Street Journal. Google hopes to catch rivals such as Facebook in the fast growing market.

Amazon.com — Amazon is seeking to cut back on its ties with United Parcel Service, according to a Journal article. Amazon is looking for alternatives to deal with increasing package volumes and higher costs.

T-Mobile US — The wireless carrier has been accused by YouTube of throttling the video service's content.

Apple — Apple is now offering so-called "proxy access," according to a U.S. Securities and Exchange Commission filing. That would make it easier for long-time shareholders to nominate a director for its board. Separately, FBR cut its price target on the stock to $150 per share from $175 based on prospects for weaker iPhone shipments.

Bed Bath & Beyond — The company is cutting its quarterly guidance because of lower than expected sales. For the quarter that ended November 28, the household goods retailer is now expecting earnings of $1.07 to $1.10 per share, compared to its previous forecast of $1.14 to $1.21.

Questions? Comments? Email us at marketinsider@cnbc.com